Drug
Hrs 6213
Hrs 6213: highest development phase Phase 1/2, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| HRS-6213 NCT07070349 | Phase 1/2 | Patients With Solid Tumors |
Latest
No recent events.
Follow Hrs 6213 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.